Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2011

Positive Results Reported for Biogen Idec’s Oral MS Drug in First Phase III Study

  • Biogen Idec reported positive data from a Phase III study evaluating oral BG-12 (dimethyl fumarate) therapy in patients with relapsing-remitting multiple sclerosis (RRMS). Two-year data from the Define study showed that compared with placebo therapy, treatment using oral BG-12 either twice a day (BID) or three times a day (TID) significantly reduced the proportion of patients who relapsed by 49% and 50%, respectively.

    The 1,237-patient study in addition showed that BG-12 BID and TID reduced the annualized relapse rate (ARR) by 53% and 48%, respectively, and the risk of disability progression by 38% and 34%, respectively. MRI evaluation showed that at two years, treatment with BG-12 BID and TID had, respectively, reduced the mean number of new or newly enlarging T2 hyperintense lesions by 85% and 74%, reduced the mean number of Gd+ lesions by 90% and 73%, and led to 72% and 63% lower numbers of new T1 hypointense lesions.   

    Topline data from a second Phase III study, Confirm, are expected by the end of 2011. “Results from our second Phase III trial, Confirm, will provide additional insight into BG-12’s profile, as well as a comprehensive dataset to further discussions with regulatory authorities,” comments Doug Williams, Ph.D., Biogen Idec executive vp for R&D. “The significant clinical and radiological responses in Define are further evidence that BG-12 may become an oral therapy of choice for MS patients.”


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »